Literature DB >> 21789145

Bevacizumab in the treatment of patients with advanced breast cancer: where have we landed?

L Y Dirix1, P A Van Dam, A M Prove, P B Vermeulen.   

Abstract

Vast preclinical and clinical evidence has made angiogenesis one of the hallmarks of cancer. In many human tumours, vascular endothelial growth factor (VEGF) has been identified as the crucial mediator of this process. Initial studies suggested that angiogenesis, and VEGF in particular, could be inhibited without the risk of major side effects. After the pivotal data in first-line studies in patients with colorectal cancer, numerous clinical trials have been undertaken in patients with breast cancer. This review attempts to update these investigations and define the role of anti-VEGF antibody treatment in advanced breast cancer.

Entities:  

Keywords:  advanced breast cancer; bevacizumab; chemotherapy; vascular endothelial growth factor

Year:  2010        PMID： 21789145      PMCID： PMC3126024          DOI： 10.1177/1758834010376301

Source DB:  PubMed          Journal:  Ther Adv Med Oncol        ISSN： 1758-8340            Impact factor:   8.168


  61 in total

1.  Combination of bevacizumab and 2-weekly pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer. A multicenter, single-arm phase II trial (SAKK 24/06).

Authors:  C Rochlitz; T Ruhstaller; S Lerch; C Spirig; J Huober; T Suter; M Bühlmann; M Fehr; A Schönenberger; R von Moos; R Winterhalder; D Rauch; A Müller; M Mannhart-Harms; R Herrmann; B Cliffe; M Mayer; K Zaman
Journal:  Ann Oncol       Date:  2010-07-01       Impact factor: 32.976

2.  Angiogenesis induced by "normal" human breast tissue: a probable marker for precancer.

Authors:  H M Jensen; I Chen; M R DeVault; A E Lewis
Journal:  Science       Date:  1982-10-15       Impact factor: 47.728

3.  Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.

Authors:  Kathy D Miller; Linnea I Chap; Frankie A Holmes; Melody A Cobleigh; P Kelly Marcom; Louis Fehrenbacher; Maura Dickler; Beth A Overmoyer; James D Reimann; Amy P Sing; Virginia Langmuir; Hope S Rugo
Journal:  J Clin Oncol       Date:  2005-02-01       Impact factor: 44.544

Review 4.  Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis.

Authors:  Xiaolei Zhu; Shenhong Wu; William L Dahut; Chirag R Parikh
Journal:  Am J Kidney Dis       Date:  2007-02       Impact factor: 8.860

5.  Overexpression of c-erbB-2 is related to a higher expression of vascular endothelial growth factor (VEGF) and constitutes an independent prognostic factor in primary node-positive breast cancer after adjuvant systemic treatment.

Authors:  B Linderholm; J Andersson; B Lindh; L Beckman; M Erlanson; K Edin; B Tavelin; K Grankvist; R Henriksson
Journal:  Eur J Cancer       Date:  2004-01       Impact factor: 9.162

6.  Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer.

Authors:  Silvia Dellapasqua; Francesco Bertolini; Vincenzo Bagnardi; Elisabetta Campagnoli; Eloise Scarano; Rosalba Torrisi; Yuval Shaked; Patrizia Mancuso; Aron Goldhirsch; Andrea Rocca; Elisabetta Pietri; Marco Colleoni
Journal:  J Clin Oncol       Date:  2008-09-15       Impact factor: 44.544

7.  Vascularization in primary breast carcinomas: its prognostic significance and relationship with tumor cell dissemination.

Authors:  Hari Prasad Dhakal; Bjørn Naume; Marit Synnestvedt; Elin Borgen; Rolf Kaaresen; Ellen Schlichting; Gro Wiedswang; Assia Bassarova; Karl-Erik Giercksky; Jahn M Nesland
Journal:  Clin Cancer Res       Date:  2008-04-15       Impact factor: 12.531

8.  Activated Neu/ErbB-2 induces expression of the vascular endothelial growth factor gene by functional activation of the transcription factor Sp 1.

Authors:  Günter Finkenzeller; Karin Weindel; Wolfgang Zimmermann; Gunnar Westin; Dieter Marmé
Journal:  Angiogenesis       Date:  2004       Impact factor: 9.596

9.  Angiogenesis is associated with the onset of hyperplasia in human ductal breast disease.

Authors:  J E Bluff; S R Menakuru; S S Cross; S E Higham; S P Balasubramanian; N J Brown; M W Reed; C A Staton
Journal:  Br J Cancer       Date:  2009-07-21       Impact factor: 7.640

10.  Relative microvessel area of the primary tumour, and not lymph node status, predicts the presence of bone marrow micrometastases detected by reverse transcriptase polymerase chain reaction in patients with clinically non-metastatic breast cancer.

Authors:  Ina H Benoy; Roberto Salgado; Hilde Elst; Peter Van Dam; Joost Weyler; Eric Van Marck; Simon Scharpé; Peter B Vermeulen; Luc Y Dirix
Journal:  Breast Cancer Res       Date:  2005-01-10       Impact factor: 6.466
View more
  2 in total

1.  Vaccines targeting the neovasculature of tumors.

Authors:  Agata Matejuk; Qixin Leng; Szu-Ting Chou; Archibald J Mixson
Journal:  Vasc Cell       Date:  2011-03-08

2.  A Real-World Multicentre Retrospective Study of Paclitaxel-Bevacizumab and Maintenance Therapy as First-Line for HER2-Negative Metastatic Breast Cancer.

Authors:  Teresa Gamucci; Lucia Mentuccia; Clara Natoli; Isabella Sperduti; Alessandra Cassano; Andrea Michelotti; Luigi Di Lauro; Domenico Sergi; Alessandra Fabi; Maria G Sarobba; Paolo Marchetti; Maddalena Barba; Emanuela Magnolfi; Marcello Maugeri-Saccà; Ernesto Rossi; Valentina Sini; Antonino Grassadonia; Domenica Pellegrini; Antonino Astone; Cecilia Nisticò; Franco Angelini; Angela Vaccaro; Arianna Pellegrino; Claudia De Angelis; Michela Palleschi; Luca Moscetti; Ilaria Bertolini; Simonetta Buglioni; Antonio Giordano; Laura Pizzuti; Patrizia Vici
Journal:  J Cell Physiol       Date:  2016-11-30       Impact factor: 6.384
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.